IMAC (IMAC) Competitors $1.13 +0.02 (+1.80%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends IMAC vs. BEAT, CRDL, TRAW, STRM, RANI, KRMD, ME, PDSB, ELYM, and RMTIShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include BioTelemetry (BEAT), Cardiol Therapeutics (CRDL), Traws Pharma (TRAW), Streamline Health Solutions (STRM), Rani Therapeutics (RANI), KORU Medical Systems (KRMD), 23andMe (ME), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), and Rockwell Medical (RMTI). These companies are all part of the "medical" sector. IMAC vs. BioTelemetry Cardiol Therapeutics Traws Pharma Streamline Health Solutions Rani Therapeutics KORU Medical Systems 23andMe PDS Biotechnology Eliem Therapeutics Rockwell Medical IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Does the MarketBeat Community favor IMAC or BEAT? BioTelemetry received 319 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.31% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformIMACOutperform Votes7160.17% Underperform Votes4739.83% BioTelemetryOutperform Votes39063.31% Underperform Votes22636.69% Is IMAC or BEAT more profitable? BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets IMAC-75.40% -52.17% -34.51% BioTelemetry N/A -121.20%-111.73% Do analysts rate IMAC or BEAT? BioTelemetry has a consensus target price of $8.00, indicating a potential upside of 221.29%. Given BioTelemetry's higher probable upside, analysts plainly believe BioTelemetry is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMAC or BEAT? In the previous week, IMAC had 12 more articles in the media than BioTelemetry. MarketBeat recorded 12 mentions for IMAC and 0 mentions for BioTelemetry. IMAC's average media sentiment score of 0.02 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the media. Company Overall Sentiment IMAC Neutral BioTelemetry Neutral Do insiders & institutionals believe in IMAC or BEAT? 24.3% of IMAC shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 20.9% of BioTelemetry shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, IMAC or BEAT? IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500. Which has higher earnings and valuation, IMAC or BEAT? IMAC has higher revenue and earnings than BioTelemetry. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$15.22M1.97-$10.54MN/AN/ABioTelemetryN/AN/A-$14.64M-$0.62-4.02 SummaryIMAC beats BioTelemetry on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAC vs. The Competition Export to ExcelMetricIMACSpecialty Outpatient Clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.93M$15.37M$5.39B$8.53BDividend YieldN/AN/A5.13%4.14%P/E RatioN/AN/A113.8115.12Price / Sales1.971.971,483.2593.03Price / CashN/AN/A39.6434.05Price / Book1.641.644.665.02Net Income-$10.54M-$10.54M$119.06M$225.46M7 Day Performance-11.02%-11.02%0.79%0.37%1 Month Performance2.73%2.73%5.65%3.57%1 Year Performance-28.48%-28.48%36.76%29.42% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMACIMACN/A$1.13+1.8%N/A-30.7%$29.93M$15.22M0.00106BEATBioTelemetry2.5627 of 5 stars$2.44+0.4%$8.00+227.9%+94.5%$64.81MN/A-3.941,700Upcoming EarningsShort Interest ↓CRDLCardiol Therapeutics2.1279 of 5 stars$1.86+0.5%$8.75+370.4%+122.6%$128.34M$60,000.00-5.6420TRAWTraws Pharma1.7007 of 5 stars$5.06+2.4%N/AN/A$128.05M$226,000.00-0.0417Positive NewsGap UpSTRMStreamline Health Solutions2.6479 of 5 stars$2.02-3.3%N/A-64.7%$125.30M$20.30M-0.41130Analyst ForecastGap UpRANIRani Therapeutics3.1546 of 5 stars$2.33+0.9%$11.71+402.8%+20.9%$124.45M$2.72M-1.97110Positive NewsKRMDKORU Medical Systems1.3649 of 5 stars$2.70+4.7%$3.33+23.5%+20.5%$123.81M$30.82M-10.8080Short Interest ↑ME23andMe1.8936 of 5 stars$5.05+4.1%$9.40+86.1%-71.6%$123.78M$219.64M-0.19770Gap DownPDSBPDS Biotechnology0.8402 of 5 stars$3.33+0.9%$14.25+327.9%-23.4%$122.61MN/A-2.7320Analyst UpgradeELYMEliem TherapeuticsN/A$4.11-3.5%N/A+44.3%$122.28MN/A-7.7520RMTIRockwell Medical4.0706 of 5 stars$3.93+2.6%$9.00+129.0%+104.9%$121.95M$83.61M-23.12300Gap Up Related Companies and Tools Related Companies BioTelemetry Competitors Cardiol Therapeutics Competitors Traws Pharma Competitors Streamline Health Solutions Competitors Rani Therapeutics Competitors KORU Medical Systems Competitors 23andMe Competitors PDS Biotechnology Competitors Eliem Therapeutics Competitors Rockwell Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMAC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
